pharma · Carcinoma, Renal Cell · Human Immunodeficiency Virus (HIV) Infection
Merck KGaA, Darmstadt
Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt is a pharma organization headquartered in Darmstadt, DE. Primary therapeutic focus areas include Carcinoma, Renal Cell, Human Immunodeficiency Virus (HIV) Infection, Systemic Lupus Erythematosus, So
Frankfurter Str. 250, Darmstadt, 64293, DE HQ
7,364 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Frankfurter Str. 250, Darmstadt, 64293, DE
- Employees
- 7,364
- Programs
- 63
- Drugs
- 50
- Patents
- 0
Vericiguat
Phase 3 · small molecule · Chronic Heart Failure With Reduced Ejection Fraction
Vericiguat for Chronic Heart Failure With Reduced Ejection Fraction is a Phase 3 program (small_molecule) at Merck KGaA, Darmstadt, Germany with 1 ClinicalTrials.gov record(s).
Internal code 1242-035
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Merck KGaA, Darmstadt, Germany
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Chronic Heart Failure With Reduced Ejection Fraction
- Status
- completed
- Trials
- 1